 WARREN, N.J., Oct. 29, 2020 GLOBE NEWSWIRE -- Bellerophon Therapeutics, Inc. Nasdaq: BLPH Bellerophon or the Company, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today that data from its Phase 2 randomized, double-blind, placebo-controlled clinical study iNO-PF of INOpulse for the treatment of fibrotic Interstitial Lung Disease patients at risk for pulmonary hypertension will be presented at the American Thoracic Society Interstitial Lung Disease Mini Symposia and the 2020 Pulmonary Fibrosis Foundation Meeting. 